1 Department of Anatomy, Physiology and Genetics, Uniformed Services University, Bethesda, Maryland.
2 Division of Health Science, University of South Australia, Adelaide, Australia.
J Neurotrauma. 2019 Jun;36(11):1724-1737. doi: 10.1089/neu.2018.6261. Epub 2019 Mar 7.
Traumatic brain injury (TBI) triggers multiple pathobiological responses with differing onsets, magnitudes, and durations. Identifying the therapeutic window of individual pathologies is critical for successful pharmacological treatment. Dozens of experimental pharmacotherapies have been successfully tested in rodent models, yet all of them (to date) have failed in clinical trials. The differing time scales of rodent and human biological and pathological processes may have contributed to these failures. We compared rodent versus human time scales of TBI-induced changes in cerebral glucose metabolism, inflammatory processes, axonal integrity, and water homeostasis based on published data. We found that the trajectories of these pathologies run on different timescales in the two species, and it appears that there is no universal "conversion rate" between rodent and human pathophysiological processes. For example, the inflammatory process appears to have an abbreviated time scale in rodents versus humans relative to cerebral glucose metabolism or axonal pathologies. Limitations toward determining conversion rates for various pathobiological processes include the use of differing outcome measures in experimental and clinical TBI studies and the rarity of longitudinal studies. In order to better translate time and close the translational gap, we suggest 1) using clinically relevant outcome measures, primarily imaging and blood-based proteomics, in experimental TBI studies and 2) collecting data at multiple post-injury time points with a frequency exceeding the expected information content by two or three times. Combined with a big data approach, we believe these measures will facilitate the translation of promising experimental treatments into clinical use.
创伤性脑损伤 (TBI) 引发多种具有不同起始时间、程度和持续时间的病理生物学反应。确定个体病变的治疗窗对于成功的药物治疗至关重要。数十种实验性药物治疗已在啮齿动物模型中成功测试,但迄今为止,所有这些治疗方法都在临床试验中失败。啮齿动物和人类的生物学和病理过程的时间尺度的不同可能导致了这些失败。我们根据已发表的数据比较了 TBI 诱导的大脑葡萄糖代谢、炎症过程、轴突完整性和水动态平衡的变化在啮齿动物和人类中的时间尺度。我们发现这些病理学的轨迹在两种物种中的时间尺度不同,而且似乎没有啮齿动物和人类病理生理过程之间的通用“转换率”。例如,与大脑葡萄糖代谢或轴突病变相比,炎症过程在啮齿动物中似乎具有更短的时间尺度。确定各种病理生物学过程的转换率存在一些限制,包括在实验性和临床性 TBI 研究中使用不同的结局测量以及纵向研究的罕见性。为了更好地转化时间并缩小转化差距,我们建议 1) 在实验性 TBI 研究中使用临床相关的结局测量,主要是影像学和基于血液的蛋白质组学,以及 2) 在多个损伤后时间点以超过预期信息量两倍或三倍的频率收集数据。结合大数据方法,我们相信这些措施将促进有前途的实验性治疗方法转化为临床应用。